In 2 patients with Rabson–Mendenhall syndrome (9) with diabetes of long duration (>3 years) and modest or null response to metformin and insulin therapy, the SGLT2i empagliflozin (5 mg) was introduced as an add-on treatment with good (25) to excellent results (manuscript in preparation). Here, INS is linked to diabetes mellitus.